Alamar Biosciences, Inc. Common Stock (ALMR)vsDexCom Inc (DXCM)
ALMR
Alamar Biosciences, Inc. Common Stock
$27.89
+0.43%
HEALTHCARE · Cap: $2.01B
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 4848% more annual revenue ($4.97B vs $100.42M). DXCM leads profitability with a 20.1% profit margin vs -49.4%. DXCM earns a higher WallStSmart Score of 74/100 (B).
ALMR
Avoid28
out of 100
Grade: F
DXCM
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 82.1% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
0.0% earnings growth
ROE of -33.6% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMR
The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 82.1% demonstrates continued momentum.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : ALMR
The primary concerns for ALMR are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
ALMR profiles as a hypergrowth stock while DXCM is a mature play — different risk/reward profiles.
ALMR is growing revenue faster at 82.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DXCM scores higher overall (74/100 vs 28/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alamar Biosciences, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?